Exact Sciences Corp (fra:EXK) Share Price

Company Profile

Business description
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Contact
5505 Endeavor Lane
MadisonWI53719
USA
T: +1 608 284-5700
E: [email protected]
https://www.exactsciences.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
7,000

Recommended

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Shaun Ler | 30 July 2025

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.

Malik Ahmed Khan, CFA | 30 July 2025

Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.

Angus Hewitt, CFA | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	9,015.40	48.70	0.54%
CAC 40	7,861.96	4.60	0.06%
DAX 40	24,262.22	44.85	0.19%
Dow JONES (US)	44,461.28	171.71	-0.38%
FTSE 100	9,136.94	0.62	0.01%
HKSE	25,176.93	347.52	-1.36%
NASDAQ	21,129.67	31.38	0.15%
Nikkei 225	40,654.70	19.85	-0.05%
NZX 50 Index	12,855.97	80.44	-0.62%
S&P 500	6,362.90	7.96	-0.12%
S&P/ASX 200	8,756.40	51.80	0.60%
SSE Composite Index	3,615.72	6.01	0.17%